DFMO Shows Potential in the Prevention of Cervical Cancer

Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

NEW ORLEANS--In a phase I trial from M.D. Anderson Cancer Center, the chemopreventive agent difluorometh-ylornithine (DFMO) produced significant regression of cervical intraepithelial neoplasia (CIN) grade 3, Michele Follen Mitchell, MD, reported at the Society of Gynecologic Oncologists meeting.

NEW ORLEANS--In a phase I trial from M.D. Anderson Cancer Center,the chemopreventive agent difluorometh-ylornithine (DFMO) producedsignificant regression of cervical intraepithelial neoplasia (CIN)grade 3, Michele Follen Mitchell, MD, reported at the Societyof Gynecologic Oncologists meeting.

DFMO is a suicide inhibitor of ornithine decarboxylase, a stepalong the polyamine synthesis chain to carcinogenesis, and isbelieved to be a strong antiprolif-erative agent. It has beenused in the treatment of colon cancer.

The study included 30 patients treated for 30 days with one offour doses of DFMO in elixir form: 1.0, 0.5, 0.25, and 0.06 g/m²/day.

After treatment, the patients underwent biopsies for polyaminesynthesis markers followed by loop electrosurgical excision ofthe cervix for complete his-topathologic study. Blood was drawnfor red cell polyamine synthesis markers and serum ornithine andarginine levels. One patient was excluded from analysis, leaving29 for evaluation.

Despite the short duration of treatment, five patients experienceda complete response, and 10 patients had a 50% response, showingregression of the lesion from CIN 3 to CIN 1 or 2. The DNA indexconfirmed the significance of the changes from pretreatment topost-treatment biopsies, Dr. Mitchell said.

While the classic polyamine markers were modulated, these changeswere not significant, probably because of the small sample size,Dr. Mitchell said.

Tissue polyamine modulation, as measured by the spermidine/spermineratio, on the other hand, was significantly changed at a DFMOdose of 1.0 g. Serum polyamine modulation, as measured by plasmaarginine, was also significantly modulated at the 1.0 g dose.This suggests that parts of the polysynthesis chain were blocked,possibly impeding car-cinogenesis, she said.

The provides optimism for the potential use of DFMO in the preventionof cervical cancer and will be further examined in a phase IIstudy, she said.

Related Videos
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Related Content